8-K Announcements
6Material company update
May 4, 2026·SEC
Material company update
Mar 16, 2026·SEC
Material company update
Mar 11, 2026·SEC
CRISPR Therapeutics AG(CRSP)Earnings, Financials & Key Ratios
CRSP•NASDAQ
Price updated Jun 19, 2026
AboutCRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.Show more
- Revenue$4M-90.0%
- EBITDA-$549M-22.7%
- Net Income-$582M-58.8%
- EPS (Diluted)-6.47-49.1%
- Gross Margin-6537.01%-2940.5%
- EBITDA Margin-15636.44%-1123.5%
- Operating Margin-16191.4%-1114.6%
- Net Margin-16569.77%-1483.5%
- ROE-30.18%-57.2%
CRSP Key Insights
CRISPR Therapeutics AG (CRSP) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 37.3%
✗Weaknesses
- ✗Profits declining 10.8% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CRSP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CRSP Price & Volume
CRISPR Therapeutics AG (CRSP) stock price & volume — 10-year historical chart
Loading chart...
CRSP Growth Metrics
CRISPR Therapeutics AG (CRSP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years30.4%
5 Years37.31%
3 Years100.42%
TTM-88.91%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-47.42%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-37.61%
Return on Capital
10 Years-18.5%
5 Years-14.03%
3 Years-19.64%
Last Year-26.62%
CRSP Recent Earnings
CRISPR Therapeutics AG (CRSP) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 3/12 qtrs (27%)
Q2 2026Latest
May 4, 2026Metric
Actual
Est
EPS
$1.28-7.5%
$1.19
Rev
$1M-76.0%
$6M
Q1 2026
Feb 12, 2026Metric
Actual
Est
EPS
$1.37-19.1%
$1.15
Rev
$864,000-81.7%
$5M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$1.17+7.1%
$1.26
Rev
$889,000-90.3%
$9M
Q3 2025
Aug 4, 2025Metric
Actual
Est
EPS
$1.29+12.2%
$1.47
Rev
$892,000-90.5%
$9M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $1.28vs $1.19-7.5% | $1Mvs $6M-76.0% |
| Q1 2026 | Feb 12, 2026 | $1.37vs $1.15-19.1% | $864,000vs $5M-81.7% |
| Q4 2025 | Nov 10, 2025 | $1.17vs $1.26+7.1% | $889,000vs $9M-90.3% |
| Q3 2025 | Aug 4, 2025 | $1.29vs $1.47+12.2% | $892,000vs $9M-90.5% |
Based on last 12 quarters of dataView full earnings history →
CRSP Peer Comparison
CRISPR Therapeutics AG (CRSP) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 SGMO | 74.57M | 0.18 | -0.41 | -31.57% | -356.89% | -28.92% | ||
 PRME | 583.39M | 3.23 | -2.39 | 55.28% | -49.18% | -188.82% | 0.96 | |
 VRTX | 114.88B | 451.63 | 29.48 | 9.57% | 35.4% | 23.93% | 0.21 | |
 REGN | 63.37B | 609.94 | 14.70 | 0.99% | 29.65% | 14.32% | 0.09 | |
 ILMN | 24.6B | 161.93 | 29.71 | -0.78% | 19.43% | 32.84% | 0.94 |
Compare CRSP vs Peers
CRISPR Therapeutics AG (CRSP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CRSP Income Statement
CRISPR Therapeutics AG (CRSP) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 41M | 3.12M | 289.59M | 719K | 913.08M | 436K | 370M | 35M | 3.51M | 4.1M |
Revenue Growth % | 693.9% | -92.38% | 9169.85% | -99.75% | 126893.18% | -99.95% | 84762.39% | -90.54% | -89.97% | -88.91% |
Cost of Goods Sold | 69.8M | 113.77M | 179.36M | 269.41M | 101.18M | 110.25M | 130.25M | 110.25M | 232.96M | 224.06M |
COGS % of Revenue | 170.26% | 3641.9% | 61.94% | 37469.68% | 11.08% | 25286.7% | 35.2% | 315% | 6637.01% | - |
Gross Profit | -28.8M▲ 0% | -110.65M▼ 284.2% | 110.23M▲ 199.6% | -268.69M▼ 343.8% | 811.9M▲ 402.2% | -109.81M▼ 113.5% | 239.75M▲ 318.3% | -75.25M▼ 131.4% | -229.45M▼ 204.9% | -219.96M▲ 0% |
Gross Margin % | -70.26% | -3541.9% | 38.06% | -37369.68% | 88.92% | -25186.7% | 64.8% | -215% | -6537.01% | -5360.86% |
Gross Profit Growth % | 22.31% | -284.16% | 199.62% | -343.76% | 402.17% | -113.53% | 318.32% | -131.39% | -204.92% | - |
Operating Expenses | 105.64M | 162.07M | 63.49M | 85.75M | 438.38M | 563.35M | 462.29M | 391.32M | 338.87M | 330.19M |
OpEx % of Revenue | 257.69% | 5187.8% | 21.92% | 11925.87% | 48.01% | 129208.03% | 124.94% | 1118.05% | 9654.39% | - |
Selling, General & Admin | 35.84M | 48.29M | 63.49M | 85.75M | 99.69M | 102.46M | 76.16M | 72.98M | 73.54M | 71.43M |
SG&A % of Revenue | 87.43% | 1545.9% | 21.92% | 11925.87% | 10.92% | 23500.92% | 20.58% | 208.51% | 2095.21% | - |
Research & Development | 69.8M | 113.77M | 179.36M | 221.38M | 340.57M | 461.64M | 387.33M | 320.65M | 265.33M | 270.63M |
R&D % of Revenue | 170.26% | 3641.9% | 61.94% | 30790.26% | 37.3% | 105881.88% | 104.68% | 916.15% | 7559.17% | - |
Other Operating Expenses | -197K | -5.49M | -179.36M | -221.38M | -1.88M | -762K | -1.21M | -2.31M | 0 | -2M |
Operating Income | -64.65M▲ 0% | -158.94M▼ 145.9% | 46.74M▲ 129.4% | -354.44M▼ 858.3% | 373.53M▲ 205.4% | -673.16M▼ 280.2% | -222.54M▲ 66.9% | -466.57M▼ 109.7% | -568.32M▼ 21.8% | -550.14M▲ 0% |
Operating Margin % | -157.69% | -5087.8% | 16.14% | -49295.55% | 40.91% | -154394.72% | -60.15% | -1333.05% | -16191.4% | -13408.29% |
Operating Income Growth % | 5.11% | -145.86% | 129.41% | -858.31% | 205.39% | -280.22% | 66.94% | -109.66% | -21.81% | - |
EBITDA | -61.62M | -155.42M | 51.47M | -345.25M | 391.48M | -648.99M | -202.7M | -447.31M | -548.84M | -531.13M |
EBITDA Margin % | -150.31% | -4975.16% | 17.77% | -48018.22% | 42.87% | -148850.69% | -54.78% | -1278.02% | -15636.44% | -12944.89% |
EBITDA Growth % | 8.2% | -152.21% | 133.11% | -770.85% | 213.39% | -265.78% | 68.77% | -120.67% | -22.7% | -16.67% |
D&A (Non-Cash Add-back) | 3.02M | 3.52M | 4.72M | 9.18M | 17.95M | 24.17M | 19.84M | 19.26M | 19.48M | 19.01M |
EBIT | -64.65M | -158.94M | 46.74M | -354.44M | 373.53M | -673.16M | -222.54M | -466.57M | -568.32M | -523.9M |
Net Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Income | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -1.96M | -5.49M | 20.57M | 6.38M | 6M | 22.66M | 71.82M | 103.9M | -9.65M | -15.03M |
Pretax Income | -66.61M▲ 0% | -164.43M▼ 146.9% | 67.31M▲ 140.9% | -348.06M▼ 617.1% | 379.53M▲ 209.0% | -650.5M▼ 271.4% | -150.72M▲ 76.8% | -362.67M▼ 140.6% | -577.97M▼ 59.4% | -565.17M▲ 0% |
Pretax Margin % | -162.47% | -5263.38% | 23.24% | -48408.34% | 41.57% | -149197.25% | -40.74% | -1036.19% | -16466.24% | -13774.56% |
Income Tax | 1.75M | 553K | 448K | 809K | 1.87M | -325K | 2.89M | 3.59M | 3.63M | 3.36M |
Effective Tax Rate % | -2.63% | -0.34% | 0.67% | -0.23% | 0.49% | 0.05% | -1.92% | -0.99% | -0.63% | -0.6% |
Net Income | -68.36M▲ 0% | -164.98M▼ 141.4% | 66.86M▲ 140.5% | -348.87M▼ 621.8% | 377.66M▲ 208.3% | -650.17M▼ 272.2% | -153.61M▲ 76.4% | -366.25M▼ 138.4% | -581.6M▼ 58.8% | -568.53M▲ 0% |
Net Margin % | -166.74% | -5281.08% | 23.09% | -48520.86% | 41.36% | -149122.71% | -41.52% | -1046.43% | -16569.77% | -13856.54% |
Net Income Growth % | -194.62% | -141.35% | 140.52% | -621.8% | 208.25% | -272.16% | 76.37% | -138.43% | -58.8% | -47.42% |
Net Income (Continuing) | -68.36M | -164.98M | 66.86M | -348.87M | 377.66M | -650.17M | -153.61M | -366.25M | -581.6M | -568.53M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.71▲ 0% | -3.44▼ 101.2% | 1.17▲ 134.0% | -5.29▼ 552.1% | 4.70▲ 188.8% | -8.36▼ 277.9% | -1.94▲ 76.8% | -4.34▼ 123.7% | -6.47▼ 49.1% | -5.92▲ 0% |
EPS Growth % | 9.52% | -101.17% | 134.01% | -552.14% | 188.85% | -277.87% | 76.79% | -123.71% | -49.08% | -37.61% |
EPS (Basic) | -1.71 | -3.44 | 1.23 | -5.29 | 4.97 | -8.36 | -1.94 | -4.34 | -6.47 | - |
Diluted Shares Outstanding | 40.06M | 47.96M | 56.93M | 65.95M | 80.39M | 77.75M | 79.22M | 84.36M | 89.93M | 96.05M |
Basic Shares Outstanding | 39.97M | 47.96M | 54.39M | 65.95M | 75.95M | 77.75M | 79.22M | 84.36M | 89.93M | 96.05M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CRSP Balance Sheet
CRISPR Therapeutics AG (CRSP) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 248.38M | 466.39M | 987.55M | 1.72B | 2.42B | 1.85B | 1.91B | 1.94B | 1.99B | 2.45B |
Cash & Short-Term Investments | 239.76M | 456.65M | 943.77M | 1.69B | 2.38B | 1.82B | 1.69B | 1.9B | 1.98B | 2.44B |
Cash Only | 239.76M | 456.65M | 943.77M | 1.17B | 923.03M | 211.88M | 389.48M | 298.26M | 355.19M | 423.31M |
Short-Term Investments | 0 | 0 | 0 | 521.71M | 1.46B | 1.6B | 1.3B | 1.61B | 1.63B | 2.02B |
Accounts Receivable | 2.63M | 88K | 99K | 10.84M | 305K | 0 | 200M | 25M | 0 | 0 |
Days Sales Outstanding | 23.38 | 10.28 | 0.12 | 5.5K | 0.12 | - | 197.3 | 260.71 | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 6M | 9.66M | 0 | 0 | 8.4M | 11.7M | 6.5M | 8.31M | 9.84M | 6.58M |
Total Non-Current Assets | 22.96M | 22.62M | 79.2M | 111.35M | 334.36M | 390.03M | 321.49M | 304.9M | 279.57M | 277.46M |
Property, Plant & Equipment | 18.86M | 18.5M | 72.83M | 93.03M | 312.04M | 320.56M | 305.94M | 277.55M | 247.57M | 240.85M |
Fixed Asset Turnover | 2.17x | 0.17x | 3.98x | 0.01x | 2.93x | 0.00x | 1.21x | 0.13x | 0.01x | 0.02x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 344K | 289K | 235K | 180K | 125K | 71K | 16K | 0 | 0 | 0 |
Long-Term Investments | 3.15M | 3.16M | 5.04M | 0 | 0 | 53.13M | 1.97M | 0 | 0 | 59.02M |
Other Non-Current Assets | 3.76M | 3.83M | 6.14M | 18.14M | 22.2M | 16.27M | 13.57M | 27.35M | 32M | 36.61M |
Total Assets | 271.35M▲ 0% | 489.02M▲ 80.2% | 1.07B▲ 118.1% | 1.83B▲ 71.4% | 2.75B▲ 50.5% | 2.24B▼ 18.5% | 2.23B▼ 0.6% | 2.24B▲ 0.6% | 2.27B▲ 1.0% | 2.73B▲ 0% |
Asset Turnover | 0.15x | 0.01x | 0.27x | 0.00x | 0.33x | 0.00x | 0.17x | 0.02x | 0.00x | 0.00x |
Asset Growth % | -21.34% | 80.22% | 118.14% | 71.36% | 50.54% | -18.49% | -0.6% | 0.56% | 1.04% | 13.14% |
Total Current Liabilities | 14.51M | 27.75M | 57.11M | 94.26M | 119.88M | 121.11M | 108.79M | 87.78M | 149.12M | 136.29M |
Accounts Payable | 1.64M | 5.07M | 5.94M | 9.09M | 14.82M | 27.43M | 38.15M | 14.71M | 11.14M | 13.65M |
Days Payables Outstanding | 8.57 | 16.26 | 12.1 | 12.32 | 53.45 | 90.8 | 106.9 | 48.7 | 17.45 | 18.87 |
Short-Term Debt | 0 | 0 | 8.49M | 11.36M | 12.16M | 15.84M | 15.63M | 17.29M | 18.58M | 18.61M |
Deferred Revenue (Current) | 0 | 0 | 960K | 2.34M | 1.01M | 0 | 4.11M | 3.85M | 15.77M | 34.54M |
Other Current Liabilities | 6.97M | 14.95M | 25.9M | 38.59M | 67.51M | 58.46M | 33.13M | 33.05M | 89.55M | 88.05M |
Current Ratio | 17.12x | 16.81x | 17.29x | 18.21x | 20.17x | 15.30x | 17.54x | 22.07x | 13.32x | 17.96x |
Quick Ratio | 17.12x | 16.81x | 17.29x | 18.21x | 20.17x | 15.30x | 17.54x | 22.07x | 13.32x | 17.96x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 69M | 69.08M | 70.22M | 69.47M | 232.53M | 246.47M | 237.98M | 222.17M | 194.31M | 774.98M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 188.17M | 585.47M |
Capital Lease Obligations | 0 | 0 | 44.05M | 50.07M | 212.87M | 228.18M | 223.01M | 206.41M | 188.17M | 761.92M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 12.07M | 11.29M | 14.39M | 7.63M | 7.34M | 5.97M | 958K | 3.44M | -182.03M | 5.95M |
Total Liabilities | 83.51M | 96.82M | 127.33M | 163.73M | 352.42M | 367.58M | 346.77M | 309.95M | 343.43M | 911.26M |
Total Debt | 0 | 0 | 52.54M | 61.43M | 225.03M | 244.02M | 238.63M | 223.69M | 394.91M | 787.64M |
Net Debt | -239.76M | -456.65M | -891.23M | -1.11B | -698M | 32.14M | -150.84M | -74.56M | 39.73M | 364.33M |
Debt / Equity | - | - | 0.06x | 0.04x | 0.09x | 0.13x | 0.13x | 0.12x | 0.21x | 0.43x |
Debt / EBITDA | - | - | 1.02x | - | 0.57x | - | - | - | - | -1.48x |
Net Debt / EBITDA | - | - | -17.32x | - | -1.78x | - | - | - | - | -0.69x |
Interest Coverage | - | - | - | - | - | - | - | - | - | - |
Total Equity | 187.83M▲ 0% | 392.19M▲ 108.8% | 939.42M▲ 139.5% | 1.66B▲ 77.2% | 2.4B▲ 44.2% | 1.88B▼ 21.8% | 1.88B▲ 0.4% | 1.93B▲ 2.6% | 1.92B▼ 0.5% | 1.81B▲ 0% |
Equity Growth % | -19.33% | 108.8% | 139.53% | 77.15% | 44.18% | -21.84% | 0.39% | 2.62% | -0.53% | -16.17% |
Book Value per Share | 4.69 | 8.18 | 16.50 | 25.23 | 29.85 | 24.12 | 23.77 | 22.90 | 21.37 | 18.89 |
Total Shareholders' Equity | 187.83M | 392.19M | 939.42M | 1.66B | 2.4B | 1.88B | 1.88B | 1.93B | 1.92B | 1.81B |
Common Stock | 1.24M | 1.58M | 1.85M | 2.28M | 2.39M | 2.44M | 2.5M | 2.7M | 3.09M | 3.12M |
Retained Earnings | -125.44M | -291.57M | -224.71M | -573.58M | -195.91M | -846.09M | -999.7M | -1.37B | -1.95B | -2.07B |
Treasury Stock | 0 | -57K | -63K | -63K | -63K | -63K | -62K | -62K | -60K | -60K |
Accumulated OCI | 14K | -8K | 7K | -83K | -5.07M | -15.65M | 1.91M | 1.84M | 4.82M | -1.94M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CRSP Cash Flow Statement
CRISPR Therapeutics AG (CRSP) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -70.1M | -96.24M | 56.68M | -238.37M | 538.97M | -495.74M | -260.38M | -142.77M | -345.01M | -399.96M |
Operating CF Margin % | -170.98% | -3080.63% | 19.57% | -33152.43% | 59.03% | -113702.06% | -70.37% | -407.93% | -9829.46% | - |
Operating CF Growth % | -26.73% | -37.29% | 158.89% | -520.57% | 326.11% | -191.98% | 47.48% | 45.17% | -141.65% | -185.16% |
Net Income | -68.36M | -164.98M | 66.86M | -348.87M | 377.66M | -650.17M | -153.61M | -366.25M | -581.6M | -568.53M |
Depreciation & Amortization | 3.02M | 3.52M | 4.72M | 9.18M | 17.95M | 24.17M | 19.84M | 19.26M | 19.48M | 19.06M |
Stock-Based Compensation | 18.87M | 34.98M | 44.06M | 66.02M | 102.39M | 97.95M | 81.03M | 86.57M | 72.5M | 52.29M |
Deferred Taxes | 0 | 4.28M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 1.75M | 15.41M | -10.53M | 1.86M | 14.11M | 12.47M | -14.04M | -38.62M | 72.72M | 95.6M |
Working Capital Changes | -25.39M | 10.55M | -48.43M | 33.44M | 26.86M | 19.84M | -193.59M | 156.27M | 71.88M | 1.63M |
Change in Receivables | 531K | 2.54M | -11K | -45K | -161K | 305K | -200M | 175M | 25M | 0 |
Change in Inventory | -551.3M | 332.3M | 0 | -25.75M | -37.51M | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 546.62M | -323.28M | 0 | 25.75M | 37.51M | 5.16M | -20.25M | 0 | 44.89M | -15.54M |
Cash from Investing | -8.31M | -2.77M | 1.32M | -541.17M | -1.04B | -258.65M | 374.65M | -280.48M | -31.8M | -422.79M |
Capital Expenditures | -7.81M | -2.77M | -6.68M | -18.36M | -81.7M | -37.19M | -9.47M | -1.9M | -914K | -1.21M |
CapEx % of Revenue | 19.06% | 88.76% | 2.31% | 2553.27% | 8.95% | 8529.36% | 2.56% | 5.43% | 26.04% | 29.54% |
Acquisitions | 0 | 0 | 0 | 522.81M | 953.73M | 221.47M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -500K | 0 | 8.01M | -522.81M | -953.73M | -221.47M | -2.5M | 0 | -34M | -25M |
Cash from Financing | 2.61M | 315.93M | 430.98M | 1.02B | 250.94M | 38.59M | 62.66M | 331.98M | 426.03M | 1.01B |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 307M | 415.02M | 982.29M | 213.27M | 970K | 62.66M | 300.69M | 426.03M | 988.68M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | -57K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 2.61M | 8.94M | 15.96M | 33.86M | 37.68M | 37.62M | 0 | 31.29M | 0 | 18.66M |
Net Change in Cash | -75.76M▲ 0% | 216.9M▲ 386.3% | 489M▲ 125.4% | 236.66M▼ 51.6% | -245.52M▼ 203.7% | -715.88M▼ 191.6% | 177.59M▲ 124.8% | -91.29M▼ 151.4% | 49.3M▲ 154.0% | 180.9M▲ 0% |
Free Cash Flow | -77.91M▲ 0% | -99.01M▼ 27.1% | 49.99M▲ 150.5% | -256.72M▼ 613.5% | 457.27M▲ 278.1% | -532.93M▼ 216.5% | -269.85M▲ 49.4% | -144.68M▲ 46.4% | -345.93M▼ 139.1% | -401.18M▲ 0% |
FCF Margin % | -190.04% | -3169.4% | 17.26% | -35705.7% | 50.08% | -122231.42% | -72.93% | -413.36% | -9855.5% | -9777.63% |
FCF Growth % | -33.58% | -27.08% | 150.49% | -613.52% | 278.12% | -216.55% | 49.37% | 46.39% | -139.11% | -30.31% |
FCF per Share | -1.94 | -2.06 | 0.88 | -3.89 | 5.69 | -6.85 | -3.41 | -1.71 | -3.85 | -4.18 |
FCF Conversion (FCF/Net Income) | 1.03x | 0.58x | 0.85x | 0.68x | 1.43x | 0.76x | 1.70x | 0.39x | 0.59x | 0.71x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CRSP Key Ratios
CRISPR Therapeutics AG (CRSP) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -32.5% | -56.89% | 10.04% | -26.8% | 18.59% | -30.42% | -8.17% | -19.2% | -30.18% | -30.88% |
Return on Invested Capital (ROIC) | - | - | 72.74% | -87.84% | 24.81% | -27.98% | -9.17% | -19.5% | -22.32% | -20.89% |
Gross Margin | -70.26% | -3541.9% | 38.06% | -37369.68% | 88.92% | -25186.7% | 64.8% | -215% | -6537.01% | -5360.86% |
Net Margin | -166.74% | -5281.08% | 23.09% | -48520.86% | 41.36% | -149122.71% | -41.52% | -1046.43% | -16569.77% | -13856.54% |
Debt / Equity | - | - | 0.06x | 0.04x | 0.09x | 0.13x | 0.13x | 0.12x | 0.21x | 0.43x |
FCF Conversion | 1.03x | 0.58x | 0.85x | 0.68x | 1.43x | 0.76x | 1.70x | 0.39x | 0.59x | 0.71x |
Revenue Growth | 693.9% | -92.38% | 9169.85% | -99.75% | 126893.18% | -99.95% | 84762.39% | -90.54% | -89.97% | -88.91% |
Related:CRSP Dividend History·CRSP Revenue History·CRSP Price History·CRSP P/E History·CRSP Financial Ratios·CRSP Institutional Holders
CRSP SEC Filings & Documents
CRISPR Therapeutics AG (CRSP) SEC filings — annual & quarterly reports (10-K, 10-Q)
CRSP Frequently Asked Questions
CRISPR Therapeutics AG (CRSP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
CRISPR Therapeutics AG (CRSP) reported $4.1M in revenue for fiscal year 2025.
CRISPR Therapeutics AG (CRSP) saw revenue decline by 90.0% over the past year.
CRISPR Therapeutics AG (CRSP) reported a net loss of $568.5M for fiscal year 2025.
Dividend & Returns
CRISPR Therapeutics AG (CRSP) has a return on equity (ROE) of -30.2%. Negative ROE indicates the company is unprofitable.
CRISPR Therapeutics AG (CRSP) had negative free cash flow of $401.2M in fiscal year 2025, likely due to heavy capital investments.